Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions

Toxicology

Volumn 279, Issue 1-3, 2011, Pages 91-99

  Arozal, Wawaimuli ^a,b   Watanabe, Kenichi ^a   Veeraveedu, Punniyakoti T ^a   Ma, Meilei ^a   Thandavarayan, Rajarajan A ^a   Sukumaran, Vijayakumar ^a   Suzuki, Kenji ^c   Kodama, Makoto ^c   Aizawa, Yoshifusa ^c  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Angiotensin II receptor; Daunorubicin; Endothelin 1 receptor; Nephrotoxicity; PPAR ; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR; CELL ADHESION MOLECULE; CREATININE; CYCLOOXYGENASE 2; DAUNORUBICIN; ENDOTHELIN 1 RECEPTOR; ENDOTHELIN RECEPTOR; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; ENZYME ACTIVITY; KIDNEY FUNCTION; KIDNEY PARENCHYMA; LIPID BLOOD LEVEL; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RECEPTOR DOWN REGULATION; RENAL PROTECTION; SPRAGUE DAWLEY RAT; UREA BLOOD LEVEL;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; BENZIMIDAZOLES; BENZOATES; DAUNORUBICIN; GENE EXPRESSION REGULATION; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A;

RATTUS;

EID: 78650030818     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.09.013     Document Type: Article

References (74)

1. Arozal W., Watanabe K., Veeraveedu P.T., Ma M., Thandavarayan R.A., Sukumaran V., Suzuki K., Kodama M., Aizawa Y. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 2010, 274:18-26.
2. Atlas S.A. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J. Manage. Care Pharm. 2007, 13(Suppl B):9-20.
3. Bae E.H., Kim I.J., Ma S.K., Kim S.W. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats. Hypertens. Res. 2010, 33:255-262.
4. Barnett A. Preventing renal complications in type 2 diabetes: results of diabetics exposed to telmisartan and enalapril trial. J. Am. Soc. Nephrol. 2006, 17:S132-S135.
5. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002.
6. Berl T. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J. Renin Angiotensin Aldosterone Syst. 2009, 10:1-8.
7. Bien S., Riad A., Ritter C.A., Gratz M., Olshausen F., Westermann D., Grube M., Krieg T., Ciecholewski S., Felix S.B., Staudt A., Schultheiss H.P., Ewert R., Völker U., Tschöpe C., Kroemer H.K. The endothelin receptor blocker Bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007, 67:10428-10435.
8. Boffa J.J., Tharaux P.L., Dussaule J.C., Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001, 37(2 Part 2):490-496.
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
10. Cianchetti S., Del Fiorentino A., Colognato R., Di Stefano R., Franzoni F., Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008, 198:22-28.
11. Deng D.X., Jiang J., Garcia B., Zhong R., Chakrabarti S. Endothelin-1, endothelin-3 and their receptors (endothelin(A) and endothelin(B)) in chronic renal transplant rejection in rats. Transplant. Int. 2000, 13:175-182.
12. Dioudis C., Grekas D., Papageorgiou G., Iliadis S., Botsoglou N., Zilidis C., Tourkantonis A., Trakatellis A. Lipid peroxidation and antioxidant defense mechanisms in rat renal tissue after daunorubicin administration. Renal Fail. 1996, 18:537-543.
13. Dziegiel P., Jethon Z., Suder E., Sopel M., Rabczyński J., Surowiak P., Zabel M. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Exp. Toxicol. Pathol. 2002, 53:433-439.
14. Dziegiel P., Suder E., Surowiak P., Jethon Z., Rabczyński J., Januszewska L., Sopel M. Role of exogenous melatonin in reducing the nephrotoxic effect of daunorubicin and doxorubicin in the rat. J. Pineal Res. 2002, 33:95-100.
15. Ebihara I., Nakamura T., Tomino Y., Koide H. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis. Nephrol. Dial. Transplant. 1997, 12:1001-1006.
16. Forbes J.M., Jandeleit-Dahm K., Allen T.J., Hewitson T.D., Becker G.J., Jones C.L. Endothelin and endothelin A/B receptors are increased after ischaemic acute renal failure. Exp. Nephrol. 2001, 9:309-316.
17. Foster L.B., Hochholzer J.M. A single-reagent manual method for directly determining urea nitrogen in serum. Clin. Chem. 1971, 17:921-925.
18. Frank K., Zeier M., Gross M.L., Waldherr R., Ritz E., Amann K. Comprehensive immunohistological analysis of the endothelin system in human kidney grafts. Nephrol. Dial. Transplant. 2006, 21:1365-1372.
19. Garvin J., Sanders K. Endothelin inhibits fluid and bicarbonate transport in part by reducing Na+/K+ ATPase activity in the rat proximal straight tubule. J. Am. Soc. Nephrol. 1991, 2:976-982.
20. Gianni L., Herman E.H., Lipshultz S.E., Minotti G., Sarvazyan, Sawyer D.B. Anthracyline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 2008, 26:3777-3784.
21. Giri S.N., Al-Bayati M.A., Du X., Schelegle E., Mohr F.C., Margolin S.B. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother. Pharmacol. 2004, 53:141-150.
22. Goddard J., Johnston N.R., Hand M.F., Cumming A.D., Rabelink T.J., Rankin A.J., Webb D.J. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004, 109:1186-1193.
23. Gurusamy N., Watanabe K., Ma M., Zhang S., Muslin A.J., Kodama M., Aizawa Y. Dominant negative 14-3-3 promotes cardiomyocyte apoptosis in early stage of type I diabetes mellitus through activation of JNK. Biochem. Biophys. Res. Commun. 2004, 320:773-780.
24. Guyton K., Bond R., Reilly C., Gilkeson G., Halushka P., Cook J. Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation. J. Leukoc. Biol. 2001, 69:631-638.
25. Hou X.W., Jiang Y., Wang L.F., Xu H.Y., Lin H.M., He X.Y., He J.J., Zhang S. Protective role of granulocyte colony-stimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. Toxicol. Lett. 2009, 187:40-44.
26. Husdan H., Rapoport A. Estimation of creatinine by the Jaffe reaction. A comparison of three methods. Clin. Chem. 1968, 14:222-238.
27. Iarussi D., Indolfi P., Casale F., Martino V., Di Tullio M.T., Calabro R. Anthracyline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr. Drugs 2005, 7:67-76.
28. Ibrahim M.A., Ashour O.M., Ibrahim Y.F., El-Bitar H.I., Gomaa W., Abdel-Rahim S.R. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol. Res. 2009, 60:378-381.
29. Imayama I., Ichiki T., Inanaga K., Ohtsubo H., Fukuyama K., Ono H., Hashiguchi Y., Sunagawa K. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc. Res. 2006, 72:184-190.
30. Iqbal M., Dubey K., Anwer T., Ashish A., Pillai K.K. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol. Rep. 2008, 60:382-390.
31. Ito M., Oguri M., Naruse A., Ito H., Suzuki Y., Satake N., Shibata S. Impaired endothelium-dependent relaxation in isolated thoracic aorta of rats with daunomycin-induced nephrosis. J. Pharmacol. Exp. Ther. 1991, 258:388-395.
32. Kirkby N.S., Hadoke P.W., Bagnall A.J., Webb D.J. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?. Br. J. Pharmacol. 2008, 153:1105-1119.
33. Kobayashi N., Ohno T., Yoshida K., Fukushima H., Mamada Y., Nomura M., Hirata H., Machida Y., Shinoda M., Suzuki N., Matsuoka H. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am. J. Hypertens. 2008, 2:576-581.
34. Ko G.J., Kang Y.S., Han S.Y., Lee M.H., Song H.K., Han K.H., Kim H.K., Han J.Y., Cha D.R. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol. Dial. Transplant. 2008, 23:2750-2760.
35. Kobori H., Nangaku M., Navar L.G., Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 2007, 59:251-287.
36. Larivière R., Lebel M., Kingma I., Grose J.H., Boucher D. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am. J. Hypertens. 1998, 11:989-997.
37. Laurent G., Jaffezou J.P. Signaling pathways activated by daunorubicin. Blood 2001, 98:913-924.
38. Lee S., Ahn D. Expression of endothelin-1 and its receptors in cisplatin-induced acute renal failure in mice. Korean J. Physiol. Pharmacol. 2008, 12:149-153.
39. Mihailovic-Stanojevic N., Jovovic D., Miloradovic Z., Grujic-Milanovic J., Jerkic M., Markovic-Lipkovski J. Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan. Nephrol. Dial. Transplant. 2009, 24:1142-1150.
40. Mohan M., Kamble S., Gadhi P., Kasture S. Protective effect of Solanum torvum on doxorubicin-induced nephrotoxicity in rats. Food Chem. Toxicol. 2010, 48:436-440.
41. Nakamura T., Fujiwara N., Kawagoe Y., Sugaya T., Ueda Y., Koide H. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. Eur. J. Clin. Invest. 2010, 40:790-796.
42. Nakhaoul F., Ramada R., Khankin E., Yaccob A., Kositch Z., Lewin M., Assady S., Abassi Z. Glomerular abundance of nephrin and podocin in experimental nephritic syndrome: different effects of antiproteinuric therapies. Am. J. Physiol. Renal Physiol. 2005, 289:F880-F890.
43. Ohtake T., Kimura M., Nishimura M., Hishida A. Roles of reactive oxygen species and antioxidant enzymes in murine daunomycin-induced nephropathy. J. Lab. Clin. Med. 1997, 129:81-88.
44. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am. J. Physiol. Renal Physiol. 2007, 292:F1141-F1150.
45. Ong A.C., Newby L.J., Dashwood M.R. Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease. Nephron Exp. Nephrol. 2003, 93(2):e80-e86.
46. Paravicini T.M., Touyz R.M. Redox signaling in hypertension. Cardiovasc. Res. 2006, 71:247-258.
47. Rahman A.M., Yusuf S.W., Ewer M.S. Anthracyline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int. J. Nanomed. 2007, 2:567-583.
48. Richard C., Lauzier B., Delemasure S., Talbot S., Ghibu S., Collin B., Senecal J., Menetrier F., Vergely C., Couture R., Rochette L. Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats. J. Cardiovasc. Pharmacol. 2008, 52:278-285.
49. Remuzzi A., Benigni A., Malanchini B., Bruzzi I., Foglieni C., Remuzzi G. ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. Kidney Int. 1995, 47:1319-1326.
50. Ruiz-Ortega M., Gómez-Garre D., Liu X.H., Blanco J., Largo R., Egido J. Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis. J. Am. Soc. Nephrol. 1997, 8:756-768.
51. Rüster C., Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 2006, 17:2985-2991.
52. Saad S.Y., Najjar T.A., Arafah M.M. Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardiomyopathy in rats. Basic Clin. Pharmacol. Toxicol. 2006, 99:412-417.
53. Sacco G., Mario B., Lopez G., Evangelista S., Manzini S., Maggi C.A. ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat. Vascul. Pharmacol. 2009, 50:166-170.
54. Sachse A., Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J. Am. Soc. Nephrol. 2007, 18:2439-2446.
55. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054-2057.
56. Shao J., Nangaku M., Inagi R., Kato H., Miyata T., Matsusaka T., Noiri E., Fujita T. Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J. Hypertens. 2007, 25:1643-1649.
57. Shibata S., Nagase M., Yoshida S., Kawachi H., Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007, 49:355-364.
58. Siehl J.M., Thiel E., Schimittel A., Hutter G., Deckert P.M., Szelenyl H., Keilholz U. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer 2005, 104:611-617.
59. Simunek T., Stirba M., Popelova O., Adamcova M., Hridina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 2009, 61:154-171.
60. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
61. Soga M., Kamal F.A., Watanabe K., Ma M., Palaniyandi S., Prakash P., Veeraveedu P.T., Mito S., Kunisaki H., Tachikawa H., Kodama M., Aizawa Y. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int. J. Cardiol. 2005, 110:378-385.
62. Sugiyama H., Kobayashi M., Wang D.H., Sunami R., Maeshima Y., Yamasaki Y., Masuoka N., Kira S., Makino S. Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acetalesemic mice. Nephrol. Dial. Transplant. 2005, 20:2670-2680.
63. Suzuki Y., Lopez-Franco O., Gomez-Garre D., Tejera N., Gomez-Guerrero C., Sugaya T., Bernal R., Blanco J., Ortega L., Egido J. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1. Am. J. Pathol. 2001, 159:1895-1904.
64. Tao L., Liu H.R., Gao E., Teng Z.P., Lopez B.L., Christopher T.A., Ma X.L., Batinic-Haberle I., Willette R.N., Ohlstein E.H., Yue T.L. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003, 108:2805-2811.
65. Tian Q., Miyazaki R., Ichiki T., Imayama I., Inanaga K., Ohtsubo H., Yano K., Takeda K., Sunagawa K. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta. Hypertension 2009, 53:798-804.
66. Toko H., Oka T., Zou Y., Sakamoto M., Mizukami M., Sano M., Yamomoto R., Sugaya T., Kumora I. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens. Res. 2002, 25:597-603.
67. Vlachojannis J., Tsakas S., Petropoulou C., Kurz P. Increased renal excretion of endothelin-1 in nephrotic patients. Nephrol. Dial. Transplant. 1997, 12:470-473.
68. Walcher D., Hess K., Heinz P., Petscher K., Vasic D., Kintscher U., Clemenz M., Hartge M., Raps K., Hombach V., Marx N. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. Hypertension 2008, 51:259-266.
69. Watanabe D., Tanabe A., Naruse M., Morikawa S., Ezaki T., Takano K. Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders. Hypertens. Res. 2009, 32:807-815.
70. Wenzel R.R., Littke T., Kuranoff S., Jürgens C., Bruck H., Ritz E., Philipp T., Mitchell A. SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 2009, 20:655-664.
71. Yamagishi S., Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med. Hypotheses 2005, 64:476-478.
72. Yoshimura A., Iwasaki S., Inui K., Ideura T., Koshikawa S., Yanagisawa M., Masaki T. Endothelin-1 and endothelin B type receptor are induced in mesangial proliferative nephritis in the rat. Kidney Int. 1995, 48:1290-1297.
73. Zheng F., Fornoni A., Elliot S.J., Guan Y., Breyer M.D., Striker L.J., Striker G.E. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPAR-gamma activation. Am. J. Physiol. Renal Physiol. 2002, 282:F639-648.
74. Zou R., Xu G., Liu X., Han M., Jiang J., Huang Q., He Y., Yao Y. PPARγ agonists inhibit TGF-β-PKA signaling in glomeruloscerosis. Acta Pharmacol. Sin. 2010, 31:43-50.